×
S&P 500   3,845.23 (+0.36%)
DOW   31,044.29 (+0.25%)
QQQ   286.97 (+0.00%)
AAPL   142.76 (+0.85%)
MSFT   265.34 (+0.95%)
META   168.99 (+0.48%)
GOOGL   2,276.99 (+0.52%)
AMZN   114.18 (+0.60%)
TSLA   690.32 (-1.27%)
NVDA   151.38 (+1.16%)
NIO   20.61 (-7.08%)
BABA   117.29 (-2.36%)
AMD   75.22 (+0.03%)
MU   57.49 (+1.34%)
CGC   2.65 (-2.21%)
T   21.06 (-0.52%)
GE   61.58 (-0.73%)
F   11.06 (-1.25%)
DIS   95.87 (-1.35%)
AMC   12.46 (-2.50%)
PFE   52.07 (+0.83%)
PYPL   73.27 (-1.52%)
NFLX   183.72 (-1.16%)
S&P 500   3,845.23 (+0.36%)
DOW   31,044.29 (+0.25%)
QQQ   286.97 (+0.00%)
AAPL   142.76 (+0.85%)
MSFT   265.34 (+0.95%)
META   168.99 (+0.48%)
GOOGL   2,276.99 (+0.52%)
AMZN   114.18 (+0.60%)
TSLA   690.32 (-1.27%)
NVDA   151.38 (+1.16%)
NIO   20.61 (-7.08%)
BABA   117.29 (-2.36%)
AMD   75.22 (+0.03%)
MU   57.49 (+1.34%)
CGC   2.65 (-2.21%)
T   21.06 (-0.52%)
GE   61.58 (-0.73%)
F   11.06 (-1.25%)
DIS   95.87 (-1.35%)
AMC   12.46 (-2.50%)
PFE   52.07 (+0.83%)
PYPL   73.27 (-1.52%)
NFLX   183.72 (-1.16%)
S&P 500   3,845.23 (+0.36%)
DOW   31,044.29 (+0.25%)
QQQ   286.97 (+0.00%)
AAPL   142.76 (+0.85%)
MSFT   265.34 (+0.95%)
META   168.99 (+0.48%)
GOOGL   2,276.99 (+0.52%)
AMZN   114.18 (+0.60%)
TSLA   690.32 (-1.27%)
NVDA   151.38 (+1.16%)
NIO   20.61 (-7.08%)
BABA   117.29 (-2.36%)
AMD   75.22 (+0.03%)
MU   57.49 (+1.34%)
CGC   2.65 (-2.21%)
T   21.06 (-0.52%)
GE   61.58 (-0.73%)
F   11.06 (-1.25%)
DIS   95.87 (-1.35%)
AMC   12.46 (-2.50%)
PFE   52.07 (+0.83%)
PYPL   73.27 (-1.52%)
NFLX   183.72 (-1.16%)
S&P 500   3,845.23 (+0.36%)
DOW   31,044.29 (+0.25%)
QQQ   286.97 (+0.00%)
AAPL   142.76 (+0.85%)
MSFT   265.34 (+0.95%)
META   168.99 (+0.48%)
GOOGL   2,276.99 (+0.52%)
AMZN   114.18 (+0.60%)
TSLA   690.32 (-1.27%)
NVDA   151.38 (+1.16%)
NIO   20.61 (-7.08%)
BABA   117.29 (-2.36%)
AMD   75.22 (+0.03%)
MU   57.49 (+1.34%)
CGC   2.65 (-2.21%)
T   21.06 (-0.52%)
GE   61.58 (-0.73%)
F   11.06 (-1.25%)
DIS   95.87 (-1.35%)
AMC   12.46 (-2.50%)
PFE   52.07 (+0.83%)
PYPL   73.27 (-1.52%)
NFLX   183.72 (-1.16%)
NASDAQ:EVAX

Evaxion Biotech A/S Stock Forecast, Price & News

$2.24
+0.01 (+0.45%)
(As of 07/6/2022 12:10 PM ET)
Add
Compare
Today's Range
$2.24
$2.30
50-Day Range
$1.60
$3.04
52-Week Range
$1.51
$25.04
Volume
275 shs
Average Volume
34,444 shs
Market Capitalization
$51.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Evaxion Biotech A/S MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
837.5% Upside
$21.00 Price Target
Short Interest
Healthy
0.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Evaxion Biotech A/S in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.27) to ($1.46) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.60 out of 5 stars

Medical Sector

923rd out of 1,426 stocks

Biological Products, Except Diagnostic Industry

155th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive EVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.

Evaxion Biotech A/S logo

About Evaxion Biotech A/S (NASDAQ:EVAX) Stock

Evaxion Biotech A/S, an artificial intelligence (AI)-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in Phase 2b trial for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are in pre-clinical stage for the treatment of infectious diseases. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate; and a clinical trial collaboration and supply agreement with MSD International GmbH and MSD International Business GmbH. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

EVAX Stock News Headlines

The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Evaxion Biotech Tops Q1 EPS by 8c
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Evaxion Biotech: Q1 Earnings Insights
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVAX
Fax
N/A
Employees
61
Year Founded
N/A

Company Calendar

Last Earnings
5/11/2022
Today
7/06/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+837.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-24,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.43 per share

Miscellaneous

Free Float
N/A
Market Cap
$51.97 million
Optionable
Not Optionable
Beta
-0.13














Evaxion Biotech A/S Frequently Asked Questions

Should I buy or sell Evaxion Biotech A/S stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Evaxion Biotech A/S stock.
View analyst ratings for Evaxion Biotech A/S
or view top-rated stocks.

What is Evaxion Biotech A/S's stock price forecast for 2022?

1 analysts have issued twelve-month price objectives for Evaxion Biotech A/S's stock. Their EVAX stock forecasts range from $21.00 to $21.00. On average, they expect Evaxion Biotech A/S's stock price to reach $21.00 in the next year. This suggests a possible upside of 837.5% from the stock's current price.
View analysts' price targets for Evaxion Biotech A/S
or view top-rated stocks among Wall Street analysts.

How has Evaxion Biotech A/S's stock performed in 2022?

Evaxion Biotech A/S's stock was trading at $4.42 at the beginning of 2022. Since then, EVAX shares have decreased by 49.3% and is now trading at $2.24.
View the best growth stocks for 2022 here
.

When is Evaxion Biotech A/S's next earnings date?

Evaxion Biotech A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Evaxion Biotech A/S
.

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) posted its quarterly earnings results on Wednesday, May, 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.10. During the same quarter last year, the company earned ($0.23) EPS.
View Evaxion Biotech A/S's earnings history
.

Who are Evaxion Biotech A/S's key executives?

Evaxion Biotech A/S's management team includes the following people:
  • Dr. Lars Aage-Staal Wegner M.D., Chief Exec. Officer (Age 47, Pay $610k)
  • Dr. Niels Iversen Moeller M.D., Co-Founder, VP of Bus. & Director (Age 43, Pay $268k)
  • Mr. Andreas Holm Mattsson, Co-Founder & Chief Innovation Officer (Age 46, Pay $290k)
  • Dr. Birgitte Rono Ph.D., Chief Scientific Officer (Age 46, Pay $309k)
  • Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D., Chief Medical Officer (Age 54, Pay $532k)
  • Mr. Bo Lokke Karmark, Chief Financial Officer (Age 57)
  • Mr. Jesper Nyegaard Nissen, COO & Interim CFO (Age 52)
  • Dr. Jürgen Langhärig EMBA, Ph.D., Head of Bus. Devel. & Member of Advisory Board

When did Evaxion Biotech A/S IPO?

(EVAX) raised $31 million in an IPO on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Evaxion Biotech A/S's stock symbol?

Evaxion Biotech A/S trades on the NASDAQ under the ticker symbol "EVAX."

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evaxion Biotech A/S's stock price today?

One share of EVAX stock can currently be purchased for approximately $2.24.

How much money does Evaxion Biotech A/S make?

Evaxion Biotech A/S (NASDAQ:EVAX) has a market capitalization of $51.97 million. The company earns $-24,530,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does Evaxion Biotech A/S have?

Evaxion Biotech A/S employs 61 workers across the globe.

How can I contact Evaxion Biotech A/S?

Evaxion Biotech A/S's mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The official website for Evaxion Biotech A/S is www.evaxion-biotech.com. The company can be reached via phone at 45-5353-1850 or via email at info@evaxion-biotech.com.

This page (NASDAQ:EVAX) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.